Antibiotic prophylaxis in patients who had undergone to prostate biopsy in between the EMA warning era: effects of fluoroquinolones in diabetic and non-diabetic patients. Results of an observational cohort study

Riccardo Bartoletti1,7 · Francesco Claps2 · Gabriele Tulone3 · Alessandro Perotti1 · Alessandro Zucchi1 · Niccolò Riccardi4 · Vincenzo Ficarra5 · Cosimo De Nunzio6 · Andrea Tubaro6 · Alchiede Simonato3

Received: 31 March 2022 / Accepted: 10 May 2022 / Published online: 10 June 2022
© The Author(s) 2022

Abstract

Purpose To investigate the effects of different antibiotic prophylaxis regimens in patients with diabetes mellitus (DM) candidates to trans-rectal ultrasound-guided prostate biopsy (TRUSPB).

Methods 143 outpatients with DM who underwent TRUSPB during the period 2018–2020 were selected from a cohort of 1150 patients in 3 different institutions. Exclusion criteria were allergies, concomitant anti-platelet therapies and uncontrolled DM. Different antibiotic prophylaxis regimens were adopted. Bacterial resistance levels to fluoroquinolones into the different communities were also collected. Univariable and multivariable binomial logistic regression analyses were used to assess the odds ratio (OR) with 95% confidence intervals (CIs) testing the risk of infective complications' occurrence after adjusting for clinical covariates.

Results Overall, DM patients were significantly associated with infective complications' occurrence (p < 0.001). No differences on the event of sepsis were found between diabetic and non-diabetic patients. Clinically relevant infections with fever > 37 °C were found in 9.1% and 1.5% (p < 0.001) in diabetic and non-diabetic patients, respectively. Trimethoprim–sulfamethoxazole and fluoroquinolones were six times more efficient than Cefixime in non-diabetic patients. Fluoroquinolones confirmed the same effect in diabetic patients although the level of resistance in the period of study decreased only from 56 to 46%.

Conclusion Fluoroquinolones were active in antibiotic prophylaxis of diabetic patients who had undergone to TRUSPB independently from the level of bacterial resistance found in the community. These results conflict with the recent European warning and support the Japanese and American guidelines on the topic.

Keywords Prostate biopsy · Infection · Antibiotic prophylaxis · Fluoroquinolones · Antibiotic resistance
Introduction

Urinary tract infections (UTIs) pose a serious threat to patients with diabetes mellitus (DM). Different authors demonstrated that the number of hospitalizations for pyelonephritis treatment and the recurrence of cystitis are more frequent in patients with DM [1]. In addition, recent studies highlighted that prolonged use of a type of hypoglycemic drugs, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors, may increase the prevalence of UTIs [2]. Trans-rectal ultrasound-guided prostate biopsy (TRUSPB) has become the most confident method for the urologist to obtain a definite response regarding early diagnosis of prostate cancer [3]. Complications after TRUSPB, such as hematuria, UTIs, acute urinary retention, lower urinary tract symptoms, have been previously described. In detail, the incidence of UTIs in patients who received TRUSPB is considerably higher than in patients who received the alternative trans-perineal approach, even if urologists are generally less confident with this technique [4, 5]. TRUSPB-related infections may lead to prolonged hospitalization as well as increased morbidity and mortality. Increased rates of infective complications after TRUSPB requiring adjunctive antibiotic treatment from 6.1 to 9.7% were found during the period 2010–2019 in Europe. In detail, 2.8% of patients developed febrile infections and 4% of them required hospitalization, while 0.12% died after TRUSPB due to sepsis [6]. Wu et al. found that body mass index, DM and preoperative characterization were independent risk factors for infection in patients who underwent TRUSPB [7]. Ding et al. recently reported the results of a univariate and multivariate logistic regression analysis on 2192 patients who underwent trans-perineal prostate biopsy. Patients with DM and history of urinary retention were more likely to have infective complications. In detail, about 34% of investigated patients had DM and infective complications were found in 1.87% of cases. Multivariate analysis highlighted an increased objective risk of complications related to DM of 2.037 times [3].

Current recommendations for antibiotic prophylaxis in candidates to TRUSPB vary in relation to national and international guidelines. The European Association of Urology (EAU) guidelines, recommended the use of povidone-iodine disinfection and targeted or augmented prophylaxis since the European Medicine Agency (EMA) warning forbad the use of Fluoroquinolones, while both the Japanese Urology Association (JUA) and American Urology Association (AUA) guidelines (last versions 2015 and 2017 respectively), still supported the use of fluoroquinolones as first choice antibiotic prophylaxis [8–11].

Hence, we retrospectively analyzed the clinical data of a multi-center cohort study subgroup of 143 diabetic patients selected from a series of 1150 patients who underwent TRUSPB between 2017 and 2019 [12] to investigate the effects of different types of antibiotic prophylaxis on symptoms suggestive of UTIs through the period of the EMA warning about the use of fluoroquinolones for the antibiotic prophylaxis of patients candidates to TRUSPB [13]. Data related to the level of antibiotic resistance to Fluoroquinolones along the period of the study have also been analyzed in each single center involved in the project.

Materials and methods

The study design consists of a retrospective multi-institutional cohort of patients who received TRUSPB during the period 2018–2020. One hundred forty three patients with DM were selected from a cohort of 1150 patients for a subgroup analysis.

Adjunctive information was collected regarding the concomitant medical therapies, co-morbidities and allergies. Patients with reported allergies to specific type of food, beverages and pharmacological compounds were excluded from the study. Similarly, patients with secondary prevention therapies for thromboembolism were excluded from the study. Abdominal ultrasound was performed independently from trans-rectal ultrasound investigations and urine culture was also collected before the biopsy to exclude the risk of concomitant urinary tract infections.

Different antibiotic prophylaxis regimens were adopted according to the protocols released from the local ethical committee of each single participating center. The antibiotic prophylaxis treatment regimen included the administration of each dose the night before the biopsy, 2 h to half an hour before the biopsy and 24 and 48 h after the biopsy according to the EAU guidelines [8, 9].

Different antibiotic prophylaxis regimens have been adopted and in particular Cefixime, trimethoprim–sulfamethoxazole, levofloxacin, prulifloxacin, ciprofloxacin and the augmented prophylaxis with ceftriaxone/fosfomycin. Dosage of antibiotic compounds was adapted to creatinine clearance and estimated glomerular filtration rate (eGFR) for each single patient. Information regarding short- and long-term complications after the biopsy, unplanned visits or hospital readmission due to different symptoms or clinical signs were also collected. Adjunctive data on the different rates of antibiotic resistance to antibiotics and fluoroquinolones in particular into the different communities of patients selected for the study along the period 2017–2019 have been also registered. The aim was to compare different types of antibiotic prophylaxis administered to the increased risk of infective complications after TRUSPB. All patients enrolled received from 12 to 16 core biopsies. General status, age, co-morbidities and co-medications were considered as relevant.
Diabetic patients were 143 (12.4%) and DM was pharmacologically controlled at biopsy. All of them had negative urine culture and none previous antibiotic therapies within the last 3 weeks. DM patients showed a higher risk of developing clinically relevant UTIs with fever > 37 °C (9.1% vs 1.5%; \( p < 0.001 \)) and rectal pain (12.6 vs 5.5%; \( p = 0.002 \)) after the TRUSPB. No significant differences on the event of sepsis have been found between the two groups. Forty-nine percent of diabetic patients and 41.5% of non-diabetic patients received fluoroquinolones as antibiotic prophylaxis respectively (\( p = 0.03 \)). The prevalence of infective complications and rectal pain after the biopsy was significantly higher in diabetic than non-diabetic patients.

**Risk factors associated with infective complications after TRUSPB**

Overall, 30 (2.6%) infective complications were found: 17 (1.7%) and 13 (9.1%) among non-DM and DM patients (\( p < 0.001 \)). Univariable and multivariable binomial logistic regression analyses adjusted for the effect of clinical covariates among non-diabetic and diabetic patients are presented in Table 2. Univariable analysis confirmed that the number of biopsy cores has to be considered as a relevant factor for developing infective complications after TRUSPB in both cohorts. A 1.29- and 1.77-fold increased risk in non-diabetic and diabetic patients was described (\( p = 0.041 \) and \( p = 0.004 \) respectively).

The univariable analysis of different compounds adopted for antibiotic prophylaxis regimens evidenced a significant effect of trimethoprim–sulfamethoxazole (\( p = 0.003 \)) and fluoroquinolones (\( p < 0.001 \)) among overall cohort (about six times more protective if compared to Cefixime) while this effect seems to be significantly reduced in favor of fluoroquinolones in DM patients. Augmented antibiotic prophylaxis (Ceftriaxone + Fosfomycin) seems to be more efficient in diabetic than non-diabetic patients.

Multivariable analysis confirmed these findings on non-diabetic patients while fluoroquinolones maintain their effects on patients with DM (about 5 times more efficient than Cefixime) but not trimethoprim–sulfamethoxazole.

Although the bacterial resistance to fluoroquinolones decreased along the period of the study into the communities located in the north, center and south areas of the country respectively, these variations are not statistically significant and did not influence the response of patients to antibiotic prophylaxis (Figure S1). No adverse events have been registered among the enrolled patients related to the type, dosage and timing of administration of each single antibiotic compound.

**Patients and clinical characteristics**

Descriptive baseline characteristics and clinico-pathological features for the general cohort of 1150 patients stratified by the presence of DM are represented in Table 1. Median age of patients at TRUSPB was 70 (IQR, 64–76) years with a median pre-biopsy prostate-specific antigen (PSA) of 7.4 ng/ml. Median number of biopsy cores taken was 12 (IQR, 12–16). The most relevant complications were hemospermia and hematuria (11% of cases), rectal bleeding (7.5%), rectal pain (6.3%), fever > 37 °C (2.4%), urinary retention (1.5%) sepsis (0.8%). DM was a surrogate endpoint of the study and due to these reasons considered for a subgroup analysis. About 41.5% of patients received antibiotic prophylaxis with fluoroquinolones, 23.1% trimethoprim–sulfamethoxazole, 20.7% augmented prophylaxis with ceftriaxone and fosfomycin, 14.6% Cefixime. Unplanned visits and hospital readmission after the biopsy were 2.5 and 0.9% respectively.

Descriptive analysis included frequencies and proportions for categorical variables. Medians and interquartile range (IQR) were reported for continuous coded variables. Mann–Whitney U or Kruskal–Wallis test was used for comparison of the continuous data and the Chi-square or Fisher’s exact test for categorical data. All tests were two-sided with a level of significance set at \( p < 0.05 \). Univariable and multivariable binomial logistic regression models were used to assess the odds ratio (OR) with 95% confidence intervals (CI) testing the risk of infective complications after adjusting for each pre-biopsy covariates. These included age at biopsy, year of biopsy, number of cores retrieved, antibiotic prophylaxis regimen adopted and presence of DM. After univariable analysis, factors with \( p < 0.2 \) were entered into the multivariable model, followed by backward elimination to determine the factors most associated with the infective complications’ occurrence. The current study represents a sensitivity analysis on a subgroup of patients with DM extracted from a large multi-center collaboration. Susceptibility tests were obtained from urine of patients who developed infective complications. Eucast breakpoints range were also determined. More efficient antibiotics were vancomycin, aminoglycosides, cephalosporins and fluoroquinolones. Cases of complicated UTIs or sepsis were handled by the Infectious Diseases Department at each participating center. Statistical analyses were performed using RStudio v.1.2.5001 (Integrated Development for RStudio). The study reports have been collected according to the STROBE statement.
Discussion

Infectious complications and antibiotic prophylaxis

The rate of infectious complications after TRUSPB varies from 1.9 to 27.7% according to different countries and showed a trend to increase in the last few years [14, 15]. The Global Prevalence Study of Infections in Urology (GPIU) confirmed that antibiotic prophylaxis often showed scarce efficacy due to antibiotic resistant bacteria [6]. Nevertheless, the comparative analysis of two different periods (2010–2014 and 2016–2019) demonstrated that most part of patients reported bothersome lower urinary tract symptoms, such as frequency and urgency, but not fever or sepsis. In particular, the rate of symptomatic cases with positive urine culture after TRUSPB raised from 1.5 to 2.4% in the two periods as well as the number of *E. coli* isolates. No statistically significant differences in terms of lethal cases and patients who required hospitalization or intensive care ward after TRUSPB were found. The bacterial resistance to antibiotics raised from 4.2 to 12.7% in the two periods, but those to fluoroquinolones, in particular, decreased from 1.3 to 0.2% probably related to the EMA warning, suggesting the limited use of these compounds in the clinical practice to avoid significant adverse events [13]. Anyhow fluoroquinolones were adopted as preferred antibiotic therapy in the case of symptoms after TRUSPB in the two periods. Similarly, the level of bacterial resistance to fluoroquinolones in the 3 centers involved in our study varied during the study period with a slight increase from 2017 to 2018 and a significant decrease in 2019, thus confirming the effects of the EMA warning. Paradoxically, univariable analysis of different antibiotics adopted for prophylaxis of TRUSPB confirmed the effects of Fluoroquinolones as six times more protective against infections than Cefixime, and without significant adverse events. The

| Variable | Overall cohort | Diabetes | P |
|----------|----------------|----------|---|
| Patients, n. (%) | 1150 (100.0) | 1007 (87.6) | 143 (12.4) |
| Age (years), median (IQR) | 70 (64–76) | 70 (64–75) | 70 (65–76) | 0.25 |
| No. of cores, median (IQR) | 12 (12–16) | 12 (12–16) | 12 (12–16) | 0.86 |
| Year of prostate biopsy, n. (%) | | | 0.25 |
| 2018 | 227 (19.7) | 203 (20.2) | 24 (16.8) |
| 2019 | 726 (63.1) | 638 (63.4) | 88 (61.5) |
| 2020 | 197 (17.1) | 166 (16.5) | 31 (21.7) |
| Antibiotic prophylaxis’ regimen, n. (%) | | | 0.03 |
| Cefixime 400 mg | 168 (14.6) | 153 (15.2) | 15 (10.5) |
| Ceftriaxone 1 g—Fosfomycin 3 g | 238 (20.7) | 207 (20.6) | 31 (21.7) |
| Trimethoprim 160 mg—Sulfamethoxazole 800 m | 266 (23.1) | 239 (23.7) | 27 (18.8) |
| Ciprofloxacin 500 mg | 25 (2.2) | 17 (1.7) | 8 (5.6) |
| Levofloxacin 500 mg | 443 (38.5) | 382 (37.9) | 61 (42.7) |
| Prulifloxacin 600 mg | 10 (0.9) | 9 (0.9) | 1 (0.7) |
| Infective complications, n. (%) | | | < 0.001 |
| Haematospermia | 126 (11.0) | 107 (10.6) | 19 (13.3) | 0.42 |
| Haematuria | 126 (11.0) | 105 (10.4) | 21 (14.7) | 0.17 |
| Rectal bleeding | 86 (7.5) | 74 (7.4) | 12 (8.4) | 0.78 |
| Fever (> 37 °C) | 28 (2.4) | 15 (1.5) | 13 (9.1) | < 0.001 |
| Sepsis | 9 (0.8) | 6 (0.6) | 3 (2.1) | 0.16 |
| Urinary retention | 17 (1.5) | 14 (1.4) | 3 (2.1) | 0.78 |
| Rectal pain | 73 (6.3) | 55 (5.5) | 18 (12.6) | 0.002 |
| Unplanned visit, n. (%) | 29 (2.5) | 25 (2.5) | 4 (2.8) | 0.9 |
| Unplanned readmission, n. (%) | 10 (0.9) | 7 (0.7) | 3 (2.1) | 0.23 |
| Center, n. (%) | | | < 0.001 |
| Palermo (Center A) | 130 (11.3) | 96 (9.5) | 34 (23.8) |
| Cuneo (Center B) | 621 (54.0) | 557 (55.3) | 64 (44.8) |
| Pisa (Center C) | 399 (34.7) | 354 (35.2) | 45 (31.5) |

QR interquartile range
same results have been obtained in multivariable analysis on patients with DM.

Other antibiotic treatments such as the augmented prophylaxis with the combination of ceftriaxone and fosfomycin and trimethoprim–sulphamethoxazole showed good results in terms of efficacy, but supposedly less efficient than fluoroquinolones. Carignan et al. in the context of a comparative study on 9391 patients who underwent to TRUSPB and received different antibiotic prophylaxis with ciprofloxacin or fosfomycin found that fosfomycin is not an effective alternative to ciprofloxacin to prevent urinary sepsis [16]. On the other hand, there is not a rational explanation regarding the superior efficacy of trimethoprim–sulfamethoxazole in non-diabetic other than in diabetic patients. Fromtling et al. experimentally described these results in normal and diabetic mice [17].

Considering the non-diabetic cohort, no differences were found about the antibiotic prophylaxis’ regimen adopted at multivariable analysis. This could be explained by the low rates of infective complications (1.7%) in this subgroup of patients. However, these findings might represent a surrogate of no need of augmented prophylaxis in such cohort of TRUSPB candidates. Conversely, DM patients were significantly more exposed to infectious complications after TRUSPB compared to their counterpart. Our experience confirmed these results. The increased risk is also related to the number of biopsy core received. In vitro studies on E. coli strains demonstrated that bacteria grow faster in urine with higher concentrations of glucose although no well-designed clinical studies confirmed this hypothesis [18].

Hyperglycemia impaired cytokine production and immune response from the host and increased adherence of type-1 fimbriated E.coli strains to uro-epithelial cells in women with DM [19–21].

### Bothersome symptoms after TRUSPB

Other significant bothersome symptoms after the biopsy were represented by rectal pain and urinary retention. No significant relationship between the type of antibiotic prophylaxis administered and short-term adverse events was found.

Within a retrospective multi-center observational study including 3350 patients undergoing TRUSPB following three different management protocols, Perán Teruel et al. found that adoption of augmented antibiotic prophylaxis

### Table 2

Univariable and multivariable binomial logistic regression analysis for prediction of infective complications among 1007 non-diabetic and 143 diabetic patients who underwent TRUSPB

| Variable                        | Univariable analysis | Multivariable analysis |
|---------------------------------|----------------------|------------------------|
|                                | OR (95% CI)          | p                      |
| Non-diabetic cohort             |                      |                        |
| Age (years), as cont           | 0.99 (0.93–1.05)     | 0.7                    |
| No. of cores, as cont          | 1.29 (1.04–1.69)     | 0.041                  |
| Year of prostate biopsy         |                      |                        |
| 2018                            | 1.00 (Ref.)          | –                      |
| 2019                            | 2.25 (0.62–14.4)     | 0.3                    |
| 2020                            | 0.61 (0.03–6.41)     | 0.7                    |
| Antibiotic prophylaxis’ regimen|                      |                        |
| Cefixime                        | 1.00 (Ref.)          | –                      |
| Ceftriaxone–Fosfomycin          | 0.61 (0.17–2.05)     | 0.4                    |
| Trimethoprim–Sulfamethoxazole   | 0.10 (0.01–0.61)     | 0.036                  |
| Fluoroquinolones                | 0.30 (0.09–1.02)     | 0.052                  |
| Diabetic cohort                 |                      |                        |
| Age (years), as cont           | 0.95 (0.88–1.02)     | 0.34                   |
| No. of cores, as cont          | 1.77 (1.25–2.79)     | –                      |
| Year of prostate biopsy         |                      |                        |
| 2018                            | 1.00 (Ref.)          | –                      |
| 2019                            | 3.29 (0.59–61.6)     | 0.3                    |
| 2020                            | 0.77 (0.03–20.1)     | 0.9                    |
| Antibiotic prophylaxis’ regimen|                      |                        |
| Cefixime                        | 1.00 (Ref.)          | –                      |
| Ceftriaxone–Fosfomycin          | 0.22 (0.05–0.95)     | 0.04                   |
| Trimethoprim–Sulfamethoxazole   | 0.12 (0.02–0.63)     | 0.01                   |
| Fluoroquinolones                | 0.02 (0.00–0.15)     | <0.001                 |

TRUSPB transrectal prostate biopsy, OR odds ratio, CI confidence interval
was the most significant variable for no complications and rectal pain occurrence. Furthermore, at multivariable analysis, the authors confirmed the independent effect of age, antibiotic prophylaxis and pre-TRUSPB PSA on the occurrence of infections [22]. Rectal pain after TRUSPB resulted more frequent in diabetic than non-diabetic patients ($p = 0.002$). TRUSPB may generate significant local pain and discomfort associated with both the insertion and movements of ultrasound probe in the rectum and the core-biopsy needle puncture [23]. Since the number of prostate biopsy cores performed of our series of patients was comparable in the 3 referral centers, rectal pain seemed mainly due to the mechanical stimulation of the rectal wall. The rectum is innervated by splanchnic sensory and somatic nerves up and down the dentate line, respectively. Somatic innervations fibers derived from the inferior rectal nerve and represent an extremely pain-sensitive area in correspondence of the prostate apex [24]. Rectal pain was found more frequent in diabetic patients compared their counterpart. The difference may be justified by the presence of neuropathic pain that may occur as forms of hyperalgesia (amplified pain from mild nocuous stimuli) or allodynia (pain caused by innocuous stimuli) [25].

Bladder outlet obstruction (BOO) in patients who underwent TRUSPB is related to different factors, such as the entity of obstructive urinary symptoms and the previous use of alpha blockers. Mechanical stimulation of the prostate by TRUSPB may generate local edema and inflammation but not partial or complete acute urinary retention episodes. Sefik et al. analyzed the results obtained in a randomized controlled trial on 112 candidates to TRUSPB. The study group patients received Tamsulosin 1 week before the biopsy and continued the therapy 1 week after. Patients of the control group did not receive adjunctive medical therapies. They found significant differences in terms of International Prostate Symptom Score (IPSS), maximum flow rate at uroflowmetry and post-void residual urine volume in favor of patients included in the study group [26].

The retrospective fashion of the study design represents a significant limitation of the study, although all findings regarding patients with DM perfectly fitted with those found in the international literature.

**Conclusion**

The results obtained are attractive due to the possible persistent active role of Fluoroquinolones in the antibiotic prophylaxis of patients’ candidates to TRUSPB as indicated by the JUA and the AUA. Fluoroquinolones were more active than other antibiotics monotherapies or augmented therapies mainly in diabetic subjects to decrease the incidence of UTIs after procedure, independently from antibiotic resistance levels found in the communities during the period of the study across the EMA warning regarding the restricted use of these compounds to avoid the risk of adverse events. However, local epidemiology of bacterial resistance to Fluoroquinolones and previous history of patient’s exposure to Fluoroquinolones therapy should be always assessed for planning an effective antibiotic prophylaxis in patients’ candidates to TRUSPB.

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1007/s00345-022-04055-7](https://doi.org/10.1007/s00345-022-04055-7).

**Author contributions** BS: protocol/project development. PTR: data collection or management. C: data analysis. BDNC manuscript writing. TZF: manuscript editing.

**Funding** Open access funding provided by Università di Pisa within the CRUI-CARE Agreement. The results of the study included in the manuscript have not been financially supported from direct or indirect interests from Companies or Organizations. The Authors have nothing to disclose regarding the above mentioned interests.

**Data availability** Not applicable.

**Code availability** Not applicable.

**Material availability** Materials included in the present work have not been previously published in other journals.

**Declarations**

**Conflict of interest** All authors have nothing to disclose regarding financial and personal relationships with other people or organizations that could inappropriately influence their work. The Authors have also nothing to disclose regarding conflict of interest with products that compete with those mentioned in their manuscript.

**Research involving human participants** This is a retrospective study conducted on already available data of office outpatients treated in accordance with the law and the national and European ethical guidelines. The patients received antibiotic prophylaxis according to the local indication and Guidelines as well as the surgical procedure of trans-rectal ultrasound-guided prostate biopsy according to the international standards. All Authors ensured that their institutions and their clinical behavior are complying with the specific requirements of the country.

**Informed consent** The informed consent for the procedure as well as the use of personal data was regularly collected from all the subjects involved into the study. Signed informed consent forms are stored in an appropriate repository of each of the participating centers and available for checking.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in
References

1. La Vignera S, Condorelli RA, Cannarella R et al (2019) Urogenital infections in patients with diabetes mellitus: beyond the conventional aspects. Int J Immunopathol Pharmacol. https://doi.org/10.1177/2058738419866582

2. Kamei J, Yamamoto S (2021) Complicated urinary tract infections in patients with diabetes mellitus. J Infect Chemother 27:1131–1136. https://doi.org/10.1016/J.IJAC.2021.05.012

3. Ding X, fei, Luand Y, Lu S ming, et al (2021) Risk factors for infection complications following transrectal ultrasound-guided transperineal prostate biopsy. World J Urol 39:2463–2467. https://doi.org/10.1007/S00345-020-03454-Y

4. Lee G, Attar K, Laniado M, Karim O (2007) Trans-rectal ultrasound guided biopsy of the prostate: nationwide diversity in practice and training in the United Kingdom. Int Urol Nephrol 39:185–188. https://doi.org/10.1007/S11255-006-6654-7

5. Marenco Jimenez JL, Claps F, Ramón-Borja JC et al (2021) Rebiopsy rate after transperineal or transrectal prostate biopsy. Prostate Int 9:78–81. https://doi.org/10.1016/J.PRNIL.2020.10.001

6. Alidjanov JF, Cai T, Bartoletti R et al (2021) The negative aftermath of prostate biopsy: prophyaxis, complications and antimicrobial stewardship; results of the global prevalence study of infections in urology 2010–2019. World J Urol 39:3423–3432. https://doi.org/10.1007/S00345-021-03614-8

7. Wu YP, Li XD, Bin KZ et al (2018) Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy. Infect Drug Resist 11:1491–1497. https://doi.org/10.2147/IDR.S171162

8. Bonkat, R. Bartoletti, F. Bruyère, et al. European association of urology (EAU) guidelines on urological infections 2021. Available at https://uroweb.org/guideline/urological-infections/

9. Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243–262. https://doi.org/10.1016/J.EURURO.2020.09.042

10. Yamamoto S, Shigemura K, Kiyota H et al (2016) Essential Japanese guidelines for the prevention of perioperative infections in the urological field. Int J Urol 23:814–824. https://doi.org/10.1111/IJU.13161

11. Lightner DJ, Wymer K, Sanchez J, Kavoussi L (2020) Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol 203:351–356. https://doi.org/10.1097/JU.0000000000000509

12. Tulone G, Giannone S, Mannone P et al (2022) Comparison of Fluoroquinolones and other antibiotic prophylaxis regimens for preventing complications in patients undergoing transrectal prostate biopsy. Antibiot (Basel, Switzerland) 11:415. https://doi.org/10.3390/ANTIBIOTICS11030415

13. Bonkat G, Pilat A, Wagenlehner F (2019) Time to adapt our practice? the european commission has restricted the use of fluoroquinolones since march 2019. Eur Urol 76:273–275. https://doi.org/10.1016/J.EURURO.2019.06.011

14. Loeb S, Vellekoop A, Ahmed HU et al (2013) Systematic review of complications of prostate biopsy. Eur Urol 64:876–892. https://doi.org/10.1016/J.EURURO.2013.05.049

15. Borghesi M, Ahmed H, Nam R et al (2017) Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 71:353–365. https://doi.org/10.1016/J.EURURO.2016.08.004

16. Carignan A, Sabbagh R, Masse V et al (2019) Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: Results from a large Canadian cohort. J Glob Antimicrob Resist 17:112–116. https://doi.org/10.1016/J.JGAR.2018.11.020

17. Fromtling RA, Abruzzo GK, Gilfillan EC et al (1985) Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice. J Antimicrob Chemother 16:735–741. https://doi.org/10.1093/JAC/16.6.735

18. Geerlings SE, Brouwer EC, Gaastra W et al (1999) Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol 48:535–539. https://doi.org/10.1099/00222615-48-6-535

19. Reinhold D, Ansorge S, Schleicher ED (1996) Elevated glucose levels stimulate transforming growth factor-beta 1 (TGF-beta 1), suppress interleukin IL-2, IL-6 and IL-10 production and DNA synthesis in peripheral blood mononuclear cells. Horm Metab Res 28:267–270. https://doi.org/10.1055/S-2007-979789

20. Geerlings SE, Brouwer EC, Van Kessel KC et al (2000) Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 30:995–1001. https://doi.org/10.1046/J.1365-2362.2000.00745.X

21. Geerlings SE, Meiland R, Van Lith EC et al (2002) Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects. Diabetes Care 25:1405–1409. https://doi.org/10.2337/DIACARE.25.8.1405

22. Perán Teruel M, Lorenzo-Gómez MF, Veiga Canuto N et al (2020) Complications of transrectal prostate biopsy in our context. International multicenter study of 3350 patients. Actas Urol Esp 44:196–204. https://doi.org/10.1016/J.ACURO.2019.11.004

23. Nazir B (2014) Pain during transrectal ultrasound-guided prostate biopsy and the role of periprostatic nerve block: what radiologists should know. Korean J Radiol 15:543–553. https://doi.org/10.3348/KJR.2014.15.5.543

24. Tanagho EA, Schmidt RA, Gomes de Araujo C (1982) Urinary obstruction rate after transperineal or transrectal prostate biopsy. Prostate Int 9:78–81. https://doi.org/10.1016/J.PRNIL.2020.10.001

25. Liao C, Zhou H, Chen H et al (2021) Patterns of nerve fibre impairments and neuronal activation in male diabetic rats with and without mechanical allodynia: a comparative study. Can J Diabetes. https://doi.org/10.1016/J.CJD.2021.08.002

26. Sefik E, Eker A, Gunlusoy B et al (2020) The effect of alpha blocker treatment prior to prostate biopsy on voiding functions, pain scores and health-related quality-of-life outcomes: a prospective randomized trial. Prog Urol 30:198–204. https://doi.org/10.1016/J.PUROL.2019.12.006

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.